p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.
p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene. 2004 Nov 18; 23(54):8766-76.
-
Yu-Tzu Tai, Ph.D.
-
Nikhil C Munshi, M.D., M.B.,B.S.
-
Dharminder Chauhan, Ph.D., J.D.
-
Teru Hideshima, Ph.D., M.D.
-
Noopur Raje, M.D.
-
Paul Gerard Guy Richardson, M.B.,B.S.
-
Kenneth Carl Anderson, M.D.